APM
MLYS icon

Avidity Partners Management’s Mineralys Therapeutics MLYS Stock Holding History

Avidity Partners Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-766,700
Closed -$13.1M – 95
2023
Q2 		$13.1M Sell
766,700
-497,100
-39% -$7.43M 0.46% 68
2023
Q1 		$19.8M Buy
+1,263,800
New +$21.3M 0.66% 49

Other funds holding MLYS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Avidity Partners Management's MLYS Position: Q3 2023 in Review

Avidity Partners Management sold out of Mineralys Therapeutics (MLYS) in Q3 2023, closing a stake of 766,700 shares — an estimated $13.1M sold.

Avidity Partners Management first reported a position in MLYS in Q1 2023 and held it in 2 quarters. The position peaked at $19.8M in Q1 2023. 77 funds tracked by Wall St. Rank hold MLYS as of Q3 2023.

  • Avidity Partners Management reported no remaining Mineralys Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Avidity Partners Management sold 766,700 Mineralys Therapeutics shares in Q3 2023, an estimated $13.1M.
  • Avidity Partners Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 2 quarters.
  • Avidity Partners Management's Mineralys Therapeutics position peaked at $19.8M in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2023.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.